Clinical Trial Update: Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC [Phase 2]

View source ↗

Summary

Phase 2 trial update for KN026 + KN046 ± XELOX in HER2-positive locally advanced resectable gastric cancer; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• KN026
• KN046
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Peking University | Conditions: HER2-positive Locally Advanced Resectable Gastric Cancer | Phase 2 | Status: RECRUITING